908 Devices Inc.

908 Devices Inc.

NNASDAQ:MASS
8.67
USD
-0.70
(-7.47%)
-0.62EPS
510.06MMarket Cap
Mar 09Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.16
0.91
4.9
1.51
1.49
1.56
1.4
1.57
1.73
Basic EPS, GAAP
-0.4
-0.68
-2.34
-0.79
-1.07
-1.13
-2.12
0.54
-0.64
Free Cash Flow per Basic Share
-0.51
-0.58
0.75
-1.07
-0.73
-0.84
-0.91
-0.69
0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.93
-2.43
5.1
6.91
5.98
5.09
3.26
3.96
3.62
Tangible Book Value per Share
-1.93
-2.43
5.1
6.91
5.4
4.53
2.16
2.95
2.31
Basic Weighted Avg Shares
19
20
5
28
31
32
34
36
38
Sales/Revenue/Turnover
22
18
27
42
47
50
48
56
66
Operating Margin (%)
-29.2
-67.57
-21.62
-52.29
-75.52
-84.91
-62.73
-45.7
-33.17
Depreciation Expense
1
1
1
1
2
2
5
4
5
Net Income, GAAP
-8
-13
-13
-22
-34
-36
-72
19
-24
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-34.17
-74.41
-47.66
-52.53
-71.64
-72.47
-151.23
34.68
-36.87
Working Capital
12
23
160
238
196
151
78
110
110
LT Debt
18
22
20
20
18
4
3
4
4
Total Equity
-50
-63
139
215
191
165
115
144
150
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-12.54
-16.57
-20.44
-51.56
15.09
-16.95

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
38
41
Market Capitalization
229
331
510

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
142
132
135
Cash, Cash Equivalents & STI
112
102
99
Accounts Receivable, Net
10
12
17
Inventories
13
14
15
Total Current Liabilities
40
49
25
Payables & Accruals
5
5
5
ST Debt
1
1
1
Deferred Revenue
9
11
12

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.93%
25.4%
Free Cash Flow
- -
-166.94%
-20.12%
Net Income, GAAP
- -
20.83%
-126.99%
Sales/Revenue/Turnover
- -
17.58%
17.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7
11
15
19
48
2025
12
13
14
17
56
2026
13
16
19
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.33
-0.37
-0.84
-0.56
-2.12
2025
1.23
-0.37
-0.42
0.12
0.54
2026
-0.32
-0.32
-0.11
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kevin J. Knopp
Full Time Employees
172
Sector
Health technology
Industry
Medical specialties
Address
44 3rd Avenue Burlington MA United States 01803
IPO Date
Dec 18, 2020
Business
908 Devices Inc. (Nasdaq: MASS) develops and commercializes purpose-built handheld chemical analysis devices leveraging mass spectrometry, microfluidic separations, and optical spectroscopy technologies for point-of-need detection and identification of hazardous substances in vital health, safety, and defense applications. The company offers MX908, a handheld mass spectrometer for trace-level analysis of solids, liquids, vapors, and aerosols including narcotics, explosives, precursors, and chemical threats; VipIR and XplorIR, portable analyzers combining FTIR and Raman spectroscopy with smart spectral processing for bulk solid/liquid identification and gas/vapor quantification at ppm levels; MX908 Beacon for enhanced area monitoring; and robotic-integrated gas detectors, serving customs and borders, hazmat/CBRN response, EOD, narcotics enforcement, and industrial monitoring markets. 908 Devices operates in the United States, Europe, the Middle East, Africa, Asia Pacific, and other regions. Founded in 2012 and headquartered at 645 Summer Street in Boston, Massachusetts, the company went public in 2020. In March 2025, Repligen Corporation acquired 908 Devices' bioprocessing analytics portfolio, including desktop devices Rebel, Maverick, Maven, and related accessories for real-time bioprocess monitoring of glucose, lactate, biomass, and media analysis, allowing 908 Devices to concentrate on handheld platforms for chemical detection; in 2024, it acquired RedWave Technology, integrating portable FTIR analyzers to expand forensics offerings and bolster optical capabilities for first responders.

Company News

  • What 908 Devices (MASS) Said on Its Q3 Earnings Call

  • 908 Devices: Solid Q3 Results

  • 908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript

  • What 908 Devices (MASS) Said on Its Q3 Earnings Call

  • 908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates

  • 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

  • 908 Devices to Participate in the Stifel 2026 Healthcare Conference

  • Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity

  • 908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026

  • Critical Contrast: TTM Technologies (NASDAQ:TTMI) versus 908 Devices (NASDAQ:MASS)

  • 908 Devices (NASDAQ:MASS) Hits New 52-Week High – Here’s What Happened

  • Masivo Silver Reports Broad Polymetallic Mineralization from Initial 2026 Drilling Program at Cerro Colorado Project, Sonora, Mexico

  • Financial Analysis: IPG Photonics (NASDAQ:IPGP) vs. 908 Devices (NASDAQ:MASS)

  • 908 Devices (NASDAQ:MASS) SVP Sells $53,726.54 in Stock

  • Insider Selling: 908 Devices (NASDAQ:MASS) SVP Sells $216,343.89 in Stock

  • Comparing 908 Devices (NASDAQ:MASS) & Plexus (NASDAQ:PLXS)

  • BlackRock Inc. Takes $16.91 Million Position in 908 Devices Inc. $MASS

  • 908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium

  • 908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates

  • 908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates